History of HPV Vaccines and Screening
From Lab Breakthroughs to Life-Saving Protection
For nearly two decades, HPV (human papillomavirus) vaccines have been a powerful tool in preventing HPV-related cancers and infections. But the story of these vaccines goes back more than 70 years, weaving together scientific breakthroughs, ethical debates, and global public health achievements. Here’s a closer look at how we went from early cancer research to vaccines that are now saving lives worldwide.
Introduction: From One Woman’s Cells to a Global Health Breakthrough
In 1951, a young mother named Henrietta Lacks sought treatment for cervical cancer at Johns Hopkins Hospital. During her care, doctors collected a small sample of her tumor without her knowledge or consent. From that sample came the first “immortal” human cell line, known as HeLa cells, which could grow and divide indefinitely in the lab. These cells became a cornerstone of modern medical research, fueling discoveries from polio vaccines to cancer treatments. Most importantly, they helped scientists uncover the link between human papillomavirus (HPV) and cervical cancer, paving the way for a revolutionary vaccine. Today, the HPV vaccine represents one of the most significant public health achievements of our time, capable of preventing nearly 90% of cervical cancers and other HPV-related diseases. This is more than a scientific timeline, it is a story about ethics, equity, and the power of research to save lives. As we look toward the global goal of eliminating cervical cancer by 2030, we honor both the science and the people who made this possible.
📌 Key Moments in the Development of HPV Vaccines
1951 – The Discovery of HeLa Cells
Henrietta Lacks, a young mother of five, was treated for cervical cancer at Johns Hopkins Hospital. Without her knowledge or consent, doctors collected a sample of her tumor. These cells, later named HeLa cells, were unique. They grew continuously in the lab, becoming the first “immortal” human cell line. HeLa cells have since been instrumental in countless medical discoveries, including research that linked HPV to cervical cancer. Today, Henrietta’s story raises important conversations about ethics, consent, and equity in medicine.
🔗 The Legacy of Henrietta Lacks and HeLa Cells – Johns Hopkins Medicine
🔗 The Immortal Life of Henrietta Lacks – JIMA
1983 – HPV Linked to Cervical Cancer
For decades, scientists believed that herpes simplex virus type 2 caused cervical cancer. This assumption was overturned when Dr. Harald zur Hausen discovered DNA from HPV types 16 and 18 in cervical cancer tissue. His work proved that HPV was the main cause of cervical cancer and opened the door to the idea that a vaccine could prevent it. In recognition of this life-changing discovery, Dr. zur Hausen was awarded the 2008 Nobel Prize in Medicine.
🔗 Nobel Prize in Physiology or Medicine 2008 – Harald zur Hausen
🔗 HPV and Cancer – NCI
Why It Matters
The HPV vaccine is more than a medical innovation, it is a cancer prevention revolution. By protecting against the viruses that cause nearly 36,000 HPV-related cancers every year in the U.S. alone (and hundreds of thousands worldwide), we can save lives and reduce health disparities. Vaccinating today means protecting the next generation.
1991 – The Building Blocks of a Vaccine
Australian researchers Ian Frazer and Jian Zhou developed virus-like particles (VLPs) – empty shells that look like HPV but contain no genetic material. These VLPs safely triggered an immune response, teaching the body to recognize and fight HPV without risking infection. At the same time, NIH scientists Doug Lowy and John Schiller made similar discoveries in the U.S., confirming that this approach could work. These findings laid the foundation for the HPV vaccines used today.
🔗 The HPV Vaccine – NIH
2002 – Clinical Trials Prove Effectiveness
Large-scale clinical trials, led by epidemiologist Laura Koutsky and others, demonstrated that the vaccine could prevent infection with HPV 16 and reduce precancerous lesions in the cervix. These results were a turning point, showing that a vaccine could prevent the leading cause of cervical cancer before it developed.
🔗 HPV Vaccine Clinical Trials – ClinicalTrials.gov
2006 – FDA Approves the First HPV Vaccine
The U.S. Food and Drug Administration (FDA) approved Gardasil 4, the first HPV vaccine, covering HPV types 6, 11, 16, and 18. The vaccine was initially recommended for girls and young women ages 9-26 to prevent cervical cancer, precancerous lesions, and genital warts. This milestone marked the first time a vaccine could prevent cancer by targeting a virus.
2009 – Protection for Boys & New Options
FDA approves Gardasil 4 for boys and young men to prevent genital warts and certain cancers, helping to curb HPV transmission and protect all genders. Around the same time, a second vaccine, Cervarix, a bivalent vaccine targeting HPV types 16 and 18, became available and was widely used in many countries (though later discontinued in the U.S. when Gardasil 9 became the preferred option).
🔗 FDA Licensure of Quadrivalent Human Papillomavirus Vaccine (HPV4, Gardasil) for Use in Males and Guidance From the Advisory Committee on Immunization Practices (ACIP) – JAMA
🔗 Cervarix: a Vaccine for the Prevention of HPV 16, 18-associated Cervical Cancer – Biologics
2014 – Gardasil 9 Launches
Gardasil 9 became available, protecting against nine HPV types (6, 11, 16, 18, 31, 33, 45, 52, and 58). This expanded coverage means that the vaccine now prevents about 90% of cervical cancers and a significant portion of other HPV-related cancers worldwide. Gardasil 9 remains the only HPV vaccine used in the United States today.
🔗 Gardasil 9 Approval and Info – FDA
🔗 Update on the New 9-Valent Vaccine for Human Papillomavirus Prevention – Cam Fam Physician
Who Should Get the HPV Vaccine?
The CDC recommends HPV vaccination for:
- All children aged 9–12 (ideal age for strongest immune response)
- Teens and adults up to age 26 if not previously vaccinated
- Adults 27–45 after consulting with a healthcare provider
2020 – Beyond Cervical Cancer
The FDA expanded Gardasil 9’s approval to include the prevention of anal, vaginal, vulvar, penile, and oropharyngeal (throat) cancers, as well as genital warts. This reinforced HPV vaccination as a tool for preventing multiple types of cancer across all genders.
🔗 Expanded Indications for Gardasil 9 – FDA
2024 – Single-Dose HPV Vaccination Recognized
The World Health Organization (WHO) endorsed a single-dose HPV vaccination schedule after new studies confirmed that one dose provides long-lasting protection comparable to two doses. This recommendation has the potential to dramatically improve access in low- and middle-income countries, where cervical cancer rates are highest.
🔗 WHO Single-Dose HPV Vaccine Recommendation
2024 and Beyond – Toward Elimination
Global cervical cancer rates are declining, thanks to vaccination programs, better screening, and treatment. The WHO has set a bold target: eliminate cervical cancer as a public health problem by 2030. This effort includes reaching 90% of girls with HPV vaccination, screening 70% of women at least twice in their lifetime, and treating 90% of women with cervical disease.
🔗 WHO’s Global Strategy to Eliminate Cervical Cancer
A Future Without Cervical Cancer
We now stand at a historic turning point. With effective HPV vaccines, better screening, and accessible treatment, WHO’s bold goal to eliminate cervical cancer as a public health threat by 2030 is not just an aspiration, it is achievable within our lifetime.
Every vaccine given, every girl and boy protected, and every screening completed moves us closer to a world where no one dies from a preventable cancer. Medical professionals, sponsors, and advocates all play a critical role in this mission. Your work ensures that the promise of science reaches every community, including those most at risk.
The history of the HPV vaccine is a story of perseverance, discovery, and progress. The next chapter is about action, and together, we can write the ending: the first cancer ever eliminated through vaccination.